Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Search
IASLC.org
IASLC Lung Cancer News
Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Home
Meetings
Meetings
Most popular
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Best of the 16th WCLC in Athens, Greece
lungcanc
EGFR-Targeted Therapy: A New Beginning
2016 ASCO Annual Meeting
IASLC Workshop in Lung Cancer Clinical Research
PASSION Results Support Further Study of Camrelizumab Plus Apatinib in SCLC
IASLC and ESMO Present 6th European Lung Cancer Conference
lungcanc
17th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting
lungcanc
2017 ASCO Annual Meeting
lungcanc
Lung Cancer Research Highlights from the 2019 ASCO Annual Meeting
lungcanc
IASLC 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology
lungcanc
IASLC 18th World Conference on Lung Cancer
lungcanc
IASLC Small Cell Lung Cancer Workshop
lungcanc
IASLC SCLC Meeting Program, Faculty to Reflect the Field’s Pivotal, Recent...
lungcanc
2019 IASLC World Conference on Lung Cancer Updates
lungcanc
IASLC WCLC 2017 Presidential Symposium Presents Leading Lung Cancer Research
lungcanc
1
2
3
...
6
Page 1 of 6
Meeting News
Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation
Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
Load more
Edit with Live CSS